New hope for kids with rare brain tumor: targeted pill shows promise
NCT ID NCT05286788
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an oral drug called MEKTOVI (binimetinib) in children and young adults with a rare brain tumor called adamantinomatous craniopharyngioma. The goal is to see if the drug can shrink or control the tumor in patients whose tumor has come back after treatment. About 38 participants aged 1 to 39 will take the drug and be monitored for response and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADAMANTINOUS CRANIOPHARYNGIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
British Columbia Children's Hospital
RECRUITINGVancouver, British Columbia, V6H 3N, Canada
-
CHU Sainte-Justine
RECRUITINGMontreal, Quebec, Canada
-
Children's Hospital Colorado
RECRUITINGAurora, Colorado, 80045, United States
-
Children's National Medical Center
RECRUITINGWashington D.C., District of Columbia, 20010, United States
-
Cincinnati Children's Hospital Medical Center
RECRUITINGCincinnati, Ohio, 45229, United States
-
Nationwide Children's Hospital
RECRUITINGColumbus, Ohio, 43205, United States
-
Nicklaus Children's Hospital
RECRUITINGMiami, Florida, 33155, United States
-
Perth Children's Hospital
RECRUITINGPerth, Western Australia, 6000, Australia
-
Queensland Children's Hospital
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
-
Sydney Children's Hospital
RECRUITINGRandwick, New South Wales, 2031, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.